About the Company
kalobios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. our mission is to improve the lives of cancer patients with innovative, humaneered®, monoclonal antibodies. kalobios' humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today's marketed antibody products. using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. our pipeline is comprised of humaneered® antibodies. these antibodies are being investigated in clinical development programs focused on treating cancer: kb004 (anti-epha3) humaneered® mab to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s phase 2 expansion portion of its phase 1/2 clinical trial in hematologic malignancies; and kb003 (anti-gm-csf) humaneered® mab that kal
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HGEN News
Biotech Industry Bankruptcy Cases: Zymergen and Humanigen
This issue of the Bankruptcy Update column focuses on the recent biotech industry bankruptcy cases of Zymergen and Humanigen.
Humanigen Inc HGENQ
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ ...
Humanigen Inc (0KB2.BE)
Humanigen, Inc. (OTC Pink: HGEN), a clinical-stage biopharmaceutical company, today announced successful dosing of ...
Humanigen Stock (OTC:HGENQ) Insider Trades
Humanigen insider trades include the CEO, CFO, board of directors and is updated today. Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading ...
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
BURLINGAME, Calif. & FONTENAY-SOUS-BOIS, France--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company ...
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead ...
Humanigen Executes Licensing Agreement for Lenzilumab™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea
About Humanigen, Inc. Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF ...
Humanigen (HGENQ) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Why Eastside Distilling Shares Are Trading Lower By Over 25%; Here Are 20 Stocks Moving Premarket
SoundHound AI, Inc.. (NASDAQ: SOUN) fell 6.1% to $2.59 in pre-market trading after jumping 40% on Friday. Humanigen, Inc. (NASDAQ: HGEN) shares fell 5.4% to $0.1357 in pre-market trading after ...
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The ...
Loading the latest forecasts...